SECTOR
Shilpa Medicare gets marketing authorization from Portugal for Tadalafil Orodispersible Films
Jan-10-2025

Shilpa Medicare has received Marketing Authorization from Portugal, Europe, for Tadalafil Orodispersible Films, 20 mg. The total Europe market for oral Tadalafil formulations is estimated at about $400 million. Shilpa Medicare becomes the first company in the World to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing Film formulation. This approval is a hybrid application and Shilpa’s product is bioequivalent to the reference product. Tadalafil is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. 

This approval has come from the company’s finished dosage form manufacturing facility, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is currently approved by MHRA UK and this is the second approval for a prescription oral mouth dissolving film product in the European/UK regulated markets from the facility. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (oral dispersible/dissolving Films and Transdermal Patches).  

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


  RELATED NEWS >>